In a report released yesterday, Joe O’Dea from Wells Fargo maintained a Buy rating on Ingersoll Rand (IR – Research Report), with a price target of $105.00. The company’s shares closed last Friday at $88.40.
According to TipRanks, O’Dea is a 4-star analyst with an average return of 7.7% and a 56.59% success rate. O’Dea covers the Industrials sector, focusing on stocks such as Johnson Controls, Eaton, and Lennox International.
Ingersoll Rand has an analyst consensus of Strong Buy, with a price target consensus of $101.50, which is a 14.82% upside from current levels. In a report released on April 8, Citi also maintained a Buy rating on the stock with a $112.00 price target.
The company has a one-year high of $96.17 and a one-year low of $53.18. Currently, Ingersoll Rand has an average volume of 2.52M.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IR in relation to earlier this year. Most recently, in February 2024, Michael J Scheske, the VP & CAO of IR sold 11,401.00 shares for a total of $999,362.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ingersoll Rand (IR) Company Description:
Ingersoll Rand Inc. is a provider of mission-critical flow control and compression equipment and associated aftermarket parts,
consumables, and services. It manufactures compressor, pump, vacuum and blower products in its markets. Its segments are Industrials, Energy,
and Medical. In the Industrials segment, the company designs, manufactures, markets and services a broad range of air compression, vacuum and blower products
across a wide array of technologies and applications. In the Medical segment, it designs, manufactures and markets specialized gas, liquid and precision syringe pumps,
and compressors for use in the medical, laboratory and biotechnology end markets.
Read More on IR:
- Ingersoll-Rand price target raised to $112 from $105 at Citi
- Ingersoll-Rand closed on the acquisitions of Controlled Fluidics, Ethafilter
- Ingersoll-Rand price target raised to $105 from $101 at Barclays
- Ingersoll-Rand’s Dover deal not a threat to bioprocessing space, says KeyBanc
- Ingersoll Rand to Acquire ILC Dover, Boosts Market Position
